The clinical success of anti-CD19 CAR T cell in treatment of refractory pre-B cell acute lymphoblastic leukaemia and diffuse large B cell lymphoma [14,17] was possible because expression of CD19 is restricted to B cell lineage and is particularly high and frequent in these B cell malignancies [20,21]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.